1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNINDS/NICHD Strategic Plan for Cerebral Palsy Research is sponsored by NINDS and NICHD. Guides research into cerebral palsy, focusing on etiology, diagnosis, therapeutic interventions, prevention, and quality of life improvements.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Universities, research institutions, healthcare providers. Confirm the full requirements in the official notice before applying.
NINDS/NICHD Strategic Plan for Cerebral Palsy Research is funded by NINDS and NICHD. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NICHD's FY2026 funding strategy applies an automatic 14 percent reduction to every new R01 below the peer-review recommended level, eliminates inflationary increases on future-year commitments, and abandons a fixed payline entirely in favor of priority-driven discretion. The structural implications for child health investigators.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read article